Juba 10,161 inimeseni on jõudnud selle ettevõtte bränding ja tema tegevusi jälgib 80 Storybooki kasutajat. Keskmiselt on ettevõtet hinnatud 5.0 punktiga aga kommenteeritud ei ole.

's activity report 2022

Magnum Medical OÜ's main activity is the wholesale of medicines and other health products.

In the fiscal year 01.05.2022-30.04.2023, the company's turnover growth was 3.6% (01.05.2021-30.04.2022 14.5%).

The company's clients are pharmacies, hospital pharmacies, healthcare institutions and other wholesale drug companies across Estonia. During the reporting period, Magnum Medical OÜ actively participated in public procurements and price inquiries of hospital owners. The same is planned for the year 2023/24. We forecast an increase in the share of public procurements and a decrease in the share of price inquiries in the sale of medicines to hospitals, which is due to the trend of hospital owners to increasingly carry out procurement procedures to support their drug purchases. We expect that smaller hospitals will gradually follow this trend.

As for the demand of outpatient pharmacies, we forecast modest growth. For the next fiscal year, we expect the company's turnover to remain at the level of 2022/23.

The trend continues to emerge, according to which new generic and innovative patented medicines are being added to the Estonian drug market, which causes the market competition of drug manufacturers to continue to intensify. The introduction of generic drugs lowers drug prices and the expected expansion of the company's product portfolio with the increase in drug selection on the market.

Generally characterizing the operating environment, it can be noted that the direct effects of the war that broke out in Ukraine on the drug supply chain have eased, but the economic environment in Estonia is deteriorating and uncertainty is increasing. Considering the general stability of the pharmaceutical sector, the company's management does not see a negative impact on the financial results of Magnum Medical OÜ due to these circumstances.

In the management's opinion, despite the changed economic environment, the company's credit risk has not significantly changed compared to the past. The company carefully monitors the payment behavior and financial condition of its customers in order to react operationally and reduce risks if necessary. The management believes that the company's liquidity risk is low and it is able to fulfill its obligations to creditors using the help of the parent company if necessary. The management estimates that the risks associated with changes in exchange rates and interest rates during the reporting year are insignificant and no transactions were concluded to hedge possible currency risks and interest rate risks.

In addition to direct business objectives, the company also pays attention to environmental friendliness, innovation, contribution to society and employee development, and modern principles of equal treatment of the workforce.

GENERAL FINANCIAL RESULTS

Company's financial indicators and ratios (in euros) 01.05.2022- 01.01.2021- 30.04.2023 30.04.2022

Sales revenue 230 195 026 222 195 226

Net profit / -loss 1 731 809 241 455

Assets 119 817 638 97 371 726

Net profit margin, % 0.8% 0.1% = Net profit / Sales revenue*100

Asset productivity, % 1.4% 0.2% = Net profit / Assets (average for the year)*100

General liquidity ratio 0.8 0.9 = Current assets / Short-term liabilities

Debtor collection period = 365 * Claims against buyers (average for the year) / 57 56 Sales revenue

Creditor payment period = 365 * Debts to suppliers (average for the year) / Sold 12 12 production cost

Equity ratio, % 17% 20% = Equity / Total assets * 100